Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease

Inclusion:

• Males and females between the ages of 18 and 75 who are diagnosed with moderate to severe Crohn's Disease defined by a CDAI score of >= 220 and <= 450, normal laboratory parameters,

• are willing and able to give informed consent, and

• are able to self-inject or have a designee or healthcare professional who can inject the study medication.

Exclusion:

• History of certain types of cancer, diagnosis of ulcerative colitis,

• female or breast feeding subjects,

• surgical bowel resection(s) with in the past 6 months,

• history of listeria,

• human immunodeficiency virus (HIV),

• central nervous system demyelinating disease or untreated TB,

• history of a poorly controlled medical condition,

• unsuccessful response to infliximab or any anti-TNF agent use in the past.